Near-Term Small-Cap Catalyst Watch

This week, we reviewed filings and press releases to identify near-term catalysts, compiling a list of small-cap companies to watch for potential spikes in trading volume, bottom confirmations, or continuation trends.

CNSP > The company's lead drug candidate, Berubicin, is the first anthracycline that appears to cross the blood-brain barrier. It is currently being evaluated in a fully enrolled, late-stage global clinical trial for glioblastoma multiforme (GBM), an aggressive and currently incurable brain cancer. The company anticipates releasing primary analysis data from this potentially pivotal trial by the end of Q1 2025.

SXTP > On February 13, 2024, our majority-owned subsidiary, 60P Australia Pty Ltd, entered a research agreement with Monash University to evaluate Tafenoquine’s efficacy against candidemia, optimize dosage, and study its pharmacokinetics. We are supporting animal studies to assess single-dose parenteral Tafenoquine against Candida spp, including C. auris. The research, conducted in Melbourne, Australia, is expected to be completed by March 2025.

IRD > Three abstracts on our investigational gene therapies have been accepted for presentation at the ARVO 2025 Meeting (May 4-8 in Salt Lake City, UT). They include 12-month data from the first three adult patients in our Phase 1/2 OPGx-LCA5 trial and preclinical results on OPGx-MERTK and OPGx-RDH12. Additionally, an FDA meeting is scheduled for March 2025 to discuss the Phase 3 trial design and registrational endpoints for OPGx-LCA5.

CARM > The Company aims to select a development candidate for its liver fibrosis program in Q1 2025, leveraging its expertise in macrophage biology and fibrotic diseases.

NOTE > Fiscal Note has entered into a definitive agreement to divest its Global Intelligence portfolio companies, Oxford Analytica and Dragonfly, to Dow Jones for $40 million, aligning with its strategic shift to focus on its core Policy platform. The deal is expected to close in Q1 2025, pending regulatory approval. FiscalNote will report its Q4 and full-year 2024 results on March 13, 2025, followed by a conference call at 5:00 p.m. ET. Additionally, the company will host investor meetings at the 37th Annual Roth Conference on March 17-18, 2025, at Laguna Cliffs Marriott.

FCUV > Our software machine auto design team made significant progress in 2024, completing the mathematical and graphical environments. The focus is now on developing the 3D-user interface for machine auto design. Our public reporting automation software is finished and in extensive testing. Additionally, we've developed a Microsoft®-based add-on to streamline financial report preparation, simplifying Form 10-Q and 10-K creation, editing, and management. We plan to commercialize this software in Q1 2025, with a cloud-based version in development.

PTN > The novel "next-generation" selective MC4R agonists are expected to begin investigational new drug (IND) enabling activities in the first quarter of 2025. Additionally, the Phase 2 BMT-801 signal detection clinical study, which combines the MC4R agonist bremelanotide with the GLP-1/GIP dual agonist tirzepatide, is expected to provide topline results by the end of February 2025. As of now, no results have been reported.

XTIA > Hangar X Studios podcast, focusing on aerospace media and innovation, will participate in the Verticon 2025 conference, held March 11-13, 2025, in Dallas, Texas. Verticon 2025 is a key event for aerospace professionals, featuring industry leaders and innovators. "We're excited to be part of Verticon 2025, a hub for aerospace innovation," said Tobin Arthur, Chief Strategy Officer of XTI Aerospace, sponsor of Hangar X Studios. "Our live podcast sessions will offer dynamic discussions and insights from some of the brightest minds in aerospace."

EVTV > The Company has delivered two high-roof vans to a New Jersey fleet operator awarded vouchers under the New Jersey Zero Emission Incentive Program (NJ ZIP), with two more vehicles expected by mid-March 2025. Additionally, Envirotech is relocating its corporate headquarters to a new 86,000-square-foot facility in Houston, Texas, set to open in Q1 2025. This move supports U.S. manufacturing expansion, strengthens fleet services, and meets the growing demand for commercial electric vehicles (EVs).

CRVO > Topline data from the first 16 weeks of the OLE phase of the RewinD-LB trial are expected in 1Q 2025.

DFLI > The Company has secured a large order for its Battle Born® All-Electric APUs from Stevens Transport, Inc., which has committed to transitioning its 2,500-truck fleet to Dragonfly Energy's lithium power solutions. The implementation will begin in Q1 2025, starting with 100 trucks equipped with the APUs, continuing through fleet completion.

PBM > On January 9, 2023, Psyence and iNGENū signed a letter of intent to advance Psyence's licensed natural psilocybin drug, beginning with a Phase IIb study. The study will use the proprietary PEX010 (25mg) sourced from Filament, testing psilocybin-assisted psychotherapy versus psychotherapy alone on 87 patients. The HAM-A scale will be the primary FDA-approved endpoint, with safety data collected throughout. The study, approved by ethics committees, will be conducted by iNGENū in Australia, with patient enrollment expected in Q1 2025.

ALXO > New ADC Clinical Candidate: Novel EGFR-directed ADC, ALX2004, planned IND submission in March 2025.

RTC > Baijiayun will hold its annual meeting in Xiamen from March 9-11, 2025, gathering company leaders from across China to discuss its future direction and strategy. CEO Yi Ma will deliver a key speech on the company’s development, strategic planning, and AI initiatives, emphasizing Baijiayun's critical period of rapid growth.

COCP > Management will join a fireside chat at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, at 11:30 a.m.The chat will be hosted by Zacks Small Cap Research Senior Analyst, Dr. David Bautz.

CERO > The company will present preclinical results of its lead compound CER-1236 in ovarian cancer at the Spring Scientific meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego, March 12-14, 2025. The poster, titled "TIM-4-L Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T Cells without Toxicity," will be presented on March 13, 2025. The poster will be available on the company’s website at 9:00 AM ET on the same day. CEO Chris Ehrlich noted that, alongside progress toward its Phase 1 trial in AML, the company continues to present promising data in ovarian cancer and other cancers, including NSCLC.

AEON > Marc Forth, AEON's President and Chief Executive Officer, will present a corporate overview at the Leerink Global Healthcare Conference being held March 10 – 12, 2025 in Miami, FL.

AFMD > Chief Executive Officer, Dr. Shawn Leland, PharmD, RPh, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025 at 2:20 p.m.

SOAR > Volato will participate in the 37th Annual Roth Conference, with CEO Matt Liotta attending the event from March 16-18, 2025. To schedule a one-on-one meeting, please contact your Roth representative. This announcement coincides with Volato’s ongoing efforts to strengthen operations and position itself for future growth.

ASBP > Today's announcement marks a key milestone for Aspire. CEO Kraig Higginson noted that the rapid absorption of our new drug delivery technology is significant and disruptive. The feasibility data for our high-dose sublingual aspirin builds on strong prior results as we prepare for the next round of clinical testing in April 2025.

FTEL > Smart Connected Equipment: Still in development since its initiation in May 2021, our smart fitness equipment is a natural extension of our core business and includes interactive exercise bikes and workout mirrors. We expect to launch commercially in April 2025, with retail products available in March 2025.

JFBR > In January 2025, we entered into a non-binding letter of intent with a Canadian public company (the Acquiror) for the proposed acquisition of Smart Repair Pro and a 49.1% stake in SciSparc Nutraceuticals Inc. (SNI), held by our subsidiary, Jeffs’ Brands Holdings Inc. The deal values Smart Repair Pro and the SNI stake at approximately $11.8 million, with the Acquiror offering up to 90% equity interest (fully diluted). The Acquiror is valued at about $3.3 million, contingent on cash holdings of at least $207,000. Post-transaction, our ownership in Smart Repair Pro and SNI will transfer to the Acquiror. The transaction is expected to close by May 30, 2025, subject to due diligence, definitive agreements, customary closing conditions, and regulatory approvals. The LOI will terminate by March 31, 2025, or upon the execution of definitive agreements. The company has entered into a definitive agreement to merge Fort Products Limited, a UK-based subsidiary, with Impact Acquisitions Corp., a capital pool company listed on the TSX Venture Exchange. The merger is expected to close by May 31, 2025, subject to the satisfaction of all conditions. However, there is no guarantee the transaction will be completed as planned.

GLTO > The company will attend the Leerink Partners Global Healthcare Conference on Wednesday, March 12, in Miami Beach, Florida, for one-on-one meetings. Additionally, the company will participate in the 37th Annual ROTH Conference with a corporate presentation and one-on-one meetings on March 17-18 in Dana Point, CA.

SMTK > The company will participate in the 37th Annual Roth Conference from March 16th-18th, one of the premier investor events in the U.S., bringing together institutional investors, industry leaders, and emerging growth companies. The conference will be held at The Laguna Cliffs Marriott in Dana Point, CA. CEO Ian Jenks and CFO Barbra Keck will attend and be available for one-on-one meetings on March 17th and 18th.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.